Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX-4430 in moderate to severe facial acne vulgaris
NCT02385760Phase 2Completed
- Sponsor
- Celtaxsys, Inc.
- Start
- Apr 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of acebilustat in acne vulgaris (2 arms), sponsored by Celtaxsys, Inc. Primary endpoints: Efficacy as measured by inflammatory lesion counts at 12 weeks and Incidence of treatment emergent adverse events at 12 weeks. Started Apr 2015; status: completed.
02
Drugs
acebilustat
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02385760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02385760.